Every practice says
stem cells.

The distinction most people have never had explained is between the laboratory and the protocol. The FDA registers and inspects the tissue establishments that process these products, and holds them to current Good Tissue Practices under 21 CFR Part 1271. What the FDA has not done is approve a specific cellular product for a specific therapeutic indication — which is why these are correctly described as investigational rather than approved. A physician applying an investigational product under their clinical judgment, sourced from a registered and accredited establishment, is operating within a well-established framework. Anyone telling you these are FDA-approved is wrong, and anyone telling you they are illegal is also wrong.

Wharton's jelly — the gelatinous tissue inside the umbilical cord — donated after a healthy first pregnancy with full maternal consent. Nothing is taken from a baby, and nothing is harvested from you. The donor is screened across five stages before any tissue is accepted: first pregnancy only, maternal age between eighteen and twenty-five, confirmed normal karyotype, a three-generation family history review, and a full infectious disease screen. Every lot that follows is released against a documented panel and carries a certificate of analysis verified by two independent laboratories.

You can, and some practices do — from bone marrow or from fat. The trade-off is that your own cells are exactly as old as you are, and they carry whatever environmental and oxidative history you have accumulated. Harvesting them also requires an additional procedure, typically aspiration under sedation or liposuction. Perinatal tissue sidesteps both issues: the cells are biologically young at collection, and there is nothing to take from you. It is also standardized and lot-verified, where an autologous harvest varies from person to person and from site to site.

In conventional culture, cells are grown flat against a plastic surface and spread out into a shape they never hold inside a body. In three-dimensional culture they form spheroids — clustered aggregates in contact with each other on every side, much closer to how cells sit in living tissue. Published research examining spheroid culture and its effect on mesenchymal cells and the exosomes they release is available at PubMed. This is a manufacturing and culture characteristic rather than a claim about comparative clinical outcomes — but it is a real difference between products, and one almost no practice will volunteer.

The category is similar. The verification often is not. What separates products in this space is provenance — the donor screen, the culture method, the release testing, and whether independent documentation travels with each lot. Those things are either documented or they are not, and you are entitled to ask. At Valere, the cellular products come from AATB-accredited, FDA-registered establishments operating under current Good Tissue Practices, with a certificate of analysis cross-checked by two independent laboratories. If a practice cannot tell you where their cells came from and how they were verified, that answer is itself informative.

The honest answer is that the evidence is developing and it is mixed. In knee osteoarthritis, meta-analyses of randomized trials have reported improvement in pain and function scores, while other analyses have found results closer to placebo and recent work has examined how much of the effect is contextual. That literature is at PubMed. The immunomodulatory characteristics of this cell source are separately documented at PubMed. What your physician will do at assessment is tell you where your specific picture sits relative to that evidence, including when the answer is that you are not a good candidate. Nobody can promise you an outcome here, and anyone who does is selling something.

Valere operates as a private-pay practice, and cellular programs are not covered by standard insurance. Cost depends on the target, the number of sessions the roadmap specifies, and what runs alongside it — which is why it is discussed after your panel is reviewed rather than quoted from a price list. What the cost reflects is the sourcing standard, the physician time, the imaging where it applies, and the follow-up panels and coaching built into the program. Payment plans and membership options are available.